Alignment among public formularies in Canada, part 3 : medicines assessed by the common drug review.: H82-29/3-2022E-PDF
"This is the last report in a three-part PMPRB series that explores current overlaps and gaps in Canadian public drug plan formularies"--Executive summary, page ii.
Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.907333&sl=0
| Department/Agency | Canada. Patented Medicine Prices Review Board, issuing body. |
|---|---|
| Title | Alignment among public formularies in Canada, part 3 : medicines assessed by the common drug review. |
| Publication type | Monograph |
| Language | [English] |
| Other language editions | [French] |
| Format | Electronic |
| Electronic document | |
| Note(s) | Issued also in French under title: Concordance des listes de médicaments des régimes publics au Canada, partie 3 : médicaments évalués par le programme commun d'évaluation des médicaments. Issued also in HTML format. Includes bibliographical references. |
| Publishing information | Ottawa, ON : Patented Medicine Prices Review Board = Conseil d'examen du prix des médicaments brevetés, February 2022. ©2022 |
| Description | 1 online resource (iii, 21 pages) : colour charts |
| ISBN | 9780660417950 |
| Catalogue number |
|
| Subject terms | Pharmaceutical services insurance -- Canada -- Statistics. Drugs -- Canada -- Statistics. Pharmaceutical policy -- Canada. |
Request alternate formats
To request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.- Date modified: